Another research group showed that the supportive potential of CTLA-4 blockage in HER2/Neu antibody and triciribine combination treatment of mouse mammary tumors was associated with increased concentrations of IFN-gamma in tumor lysates and plasma [42]. The gene discussed is ERBB2; the disease is neoplasm.